Investing.com – Denmark stocks were higher after the close on Tuesday, as gains in the Oil & Gas, Personal & Household Goods and Real Estate sectors led shares higher. At the...
SEATTLE, Oct. 06, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights' analysis, the global GLP-1 receptor agonist market is estimated to be valued at US$ 12,720.6...
Investing.com – Denmark stocks were lower after the close on Monday, as losses in the Oil & Gas, Chemicals and Software & Computer Services sectors led shares lower. At the close...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Neutral | Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Neutral | Neutral | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 148.76 | 149.17 | 146.55 | +2.21 | +1.51% | 74.66M | NASDAQ | |||
| 2,864.70 | 2,873.30 | 2,852.00 | +9.2 | +0.32% | 996.72K | NASDAQ | |||
| 339.99 | 342.46 | 337.28 | +4.65 | +1.39% | 18.70M | NASDAQ | |||
| 177.00 | 177.44 | 170.45 | +10.18 | +6.10% | 33.02M | NYSE | |||
| 639.00 | 641.00 | 632.30 | +1.03 | +0.16% | 6.35M | NASDAQ | |||
| 52.35 | 52.42 | 51.92 | +0.44 | +0.85% | 16.02M | NYSE | |||
| 119.34 | 120.18 | 117.06 | +2.52 | +2.16% | 5.80M | NYSE | |||
| 305.63 | 307.85 | 294.11 | +12.29 | +4.19% | 14.71M | NASDAQ | |||
| 55.21 | 55.22 | 54.37 | +0.74 | +1.36% | 18.23M | NASDAQ | |||
| 268.13 | 271.66 | 266.30 | -1.60 | -0.59% | 1.79M | NASDAQ | |||
| 222.90 | 223.79 | 220.37 | +0.68 | +0.31% | 15.93M | NASDAQ | |||
| 10.68 | 10.75 | 10.21 | +0.32 | +3.09% | 2.46M | NASDAQ | |||
| 11.64 | 11.68 | 11.11 | +0.55 | +4.96% | 3.18M | NASDAQ | |||
| 17.74 | 17.785 | 16.83 | +0.520 | +3.02% | 385.93K | NYSE | |||
| 166.58 | 169.55 | 166.14 | -1.22 | -0.73% | 961.30K | NYSE |
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.